Chronic pain management using AAV vectors
Adeno-associated virus (AAV) vectors are replication-deficient, nonintegrating, gene therapy vectors that offer a novel approach to chronic pain management because they can sustain pain relief with reduced side effects.
The clinical efficacy of AAV vectors depends on their unique mode of capsid assembly and ability to target specific tissues, and thus reduce side effects.
These features and the ability of AAV vectors to confer sustained pain relief make them a compelling alternative to traditional therapies.
AAV vectors present advantages over other technologies, including monoclonal antibodies (mAbs), antisense oligonucleotides (ASOs), and the CRISPR-Cas9 system, as targeted pain treatments.
Recent trials have demonstrated the potential of AAV vector-delivered cargo for pain management in osteoarthritis (OA).
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(25)00196-0
